<DOC>
	<DOCNO>NCT02506517</DOCNO>
	<brief_summary>This phase 2 study ( second phase test new drug ) see useful investigational drug call afatinib patient advance cancer change HER gene . Afatinib drug approve Health Canada treatment advance lung cancer change HER gene . Afatinib work attach block protein call HER working . HER important protein contribute growth cancer cell .</brief_summary>
	<brief_title>A Study Afatinib Patients With Advanced Cancer With Changes HER Gene</brief_title>
	<detailed_description />
	<criteria>Patients may number treatment line curative metastatic setting solid tumor . Age 18 year old . At least one measurable lesion In patient previous treatment , evidence progression cancer , per opinion investigator must present Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤1 Adequate organ function Willingness undergo fresh tumor biopsy certain timepoints Recovered previous therapy related side effect Able provide write consent Chemotherapy , biological therapy investigational agent within 3 week prior start study treatment . Hormonal treatment within 3 week prior start study treatment . Radiotherapy within 3 week prior randomization exception Major surgery within 3 week start study treatment schedule surgery project course study Known exposure epidermal growth factor receptor ( EGFR ) , human epidermal growth factor receptor ( HER ) 2 , HER3 panHER inhibitor , , limit afatinib dacomitinib . Patients inability swallow whole tablet afatinib allow study , dilute tablet must take orally . Presence malabsorption problem include , exclusively limited chronic diarrhea uncontrolled inflammatory bowel disease . History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior study entry Women childbearing potential ( WOCBP ) men able father child , unwilling abstinent use adequate contraception prior study entry , duration study participation least 28 day treatment end . Female patient childbearing potential nursing pregnant use acceptable method birth control , plan continue use method throughout study and/or agree submit pregnancy test require study . Any history concomitant condition , opinion Investigator , would compromise patient 's ability comply study interfere evaluation efficacy safety study drug Previous concomitant malignancy sit , exception Requiring treatment prohibit concomitant medication Known preexist interstitial lung disease Any history presence poorly control gastrointestinal disorder . Known active hepatitis B , active hepatitis C infection and/or know HIV carrier .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HER pathway aberration</keyword>
</DOC>